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BLACKHOUSE, BRIGGS, O’BRIENTHE ESTIMATION OF CONFID CE INTERVALSMETHODOLOGY
A Note on the Estimation of Confidence
Intervals for Cost-Effectiveness When
Costs and Effects Are Censored*
Gordon Blackhouse, MBA, Andrew H. Briggs, DPhil, Bernie J. O’Brien, PhD
Background. The relationbetweenmethodological advances
in estimation of confidence intervals (CIs) for incremental
cost-effectiveness ratios (ICER) and estimation of cost effec-
tiveness in the presence of censoring has not been explored.
The authors address the joint problem of estimating ICER
precision in the presence of censoring. Methods. Using pa-
tient-level data (n = 168) on cost and survival from a pub-
lished placebo-controlled trial, the authors compared 2
methods of measuring uncertainty with censored data: 1)
Bootstrap with censor adjustment (BCA); 2) Fieller’s method
with censor adjustment (FCA). The authors estimate the FCA
over all possible values for the correlation ( ) between costs
and effects (range= –1 to +1) and also examine the use of the
correlation between caseswithout censoring adjustment (i.e.,
simple time-on-study) for costs and effects as an approxima-
tion for . Results. Using time-on-study, which considers all
censored observations as responders (deaths), yields 0.64
life-years gained at an additional cost of 87.9 for a cost per
life-year of 137 (95% CI by bootstrap –5.9 to 392). Censoring
adjustment corrects for the bias in the time-on-study
approach and reduces the cost per life-year estimate to
132 (=72/0.54). Confidence intervals with censor adjustment
were approximately 40% wider than the base-case without
adjustment. Using the Fiellermethodwith an approximation
of based on the uncensored cost and effect correlation pro-
vides a 95%CI of (–48 to 529), which is very close to the BCA
interval of (–52 to 504). Conclusions. Adjustment for censor-
ing is necessary in cost-effectiveness studies to obtain unbi-
ased estimates of ICER with appropriate uncertainty limits.
In this study, BCA and FCAmethods, the latter with approxi-
mated covariance, are simple to compute and give similar
confidence intervals. Key words: confidence intervals; cen-
sored data; cost effectiveness analysis; Fieller’s theorem;
bootstrap.
The growing number of prospective economic eval-uations alongside clinical trials has raised several
methodological issues on the statistical analysis of cost
andcost-effectivenessdata. Twoareas of recent innova-
tion are methods for estimating confidence limits for
incremental cost-effectiveness1–4 and methods for the
analysis of censored cost data where follow-up is in-
complete.5–7 Confidence intervals for cost-effectiveness
canbe estimatednonparametrically using the resampling
technique of bootstrapping3,8 or parametrically using
Fieller’s theorem2,9 where cost and effect differences
are assumed to follow a bivariate normal distribution.
Censoringdue to incomplete follow-up is aproblem for
unbiased estimation of mean effects and costs. Build-
ing on techniques for analyzing censored effect data,
Lin et al.6 and Etzioni et al.5 developed the Kaplan-
Meier Sample Average (KMSA) method. This method
has been shown to provide a consistent estimator of
cost in the presence of censoring.
With the exception of earlier work by Gardiner et
al.10 who examined these problems in relation to deter-
ministic (i.e., nonrandom) cost functions, the method-
ological advances in estimation of confidence intervals
and censored costs have been made in apparent isola-
tion from one another: the work on confidence inter-
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vals assuming that uncensored data are available1–3,9
and the work on censoring adjustments focusing on
costs and effects separately.6,7,11,12 In this article, we use
data on costs and effects from a clinical trial to explore
2 approaches to the joint problem of estimating confi-
dence intervals with censored cost and effect data:
Censor-Adjusted Bootstrap Interval: achieved by boot-
strapping the KMSA estimator for costs and effects si-
multaneously to determine their joint density;
Censor-Adjusted Fieller’s Interval: achieved by applying
the KMSA estimator for costs and effects separately
and using these estimates in Fieller’s theorem with an
approximated covariance between costs and effects.
METHODS
Cost-Effectiveness Trial
Datawere available froma randomized trial of an an-
tiviral therapy where patient-specific data on resource
consumption, length of follow-up, and death status at
endof studywere obtained for 168patients,withn=67
assigned to control and n = 81 assigned to treatment.
Costs were calculated by weighting resource use by
unit costs (although thecurrencyof costing isnot speci-
fied). These trial data are right-censored because time-
to-death is thedependent variable andnot all individu-
als have “responded” (died) in the observation period,
so their final cost and survival is unknown. In the con-
trol arm, 22% of observations were censored, whereas
29% of observations in the treatment arm were cen-
sored. To illustrate the importance of censoring adjust-
ment, we 1st estimated cost-effectiveness with no ad-
justment for censoring and assumed that all patients
“respond” (die) at the end of their observed time-on-
study. This method yields biased (downward) esti-
mates of mean costs and effects.
Life Expectancy
Kaplan-Meier (K-M) survival curves13 for time-to-
death were estimated and, following convention,14 life
expectancy (mean survival) for treatment and control
groups was calculated as the area under the survival
curve. The timehorizon for the survival curves for both
treatment and control groups was set to the length of
follow-up of the last uncensored observation (1307
days). Standard errors for the K-M estimators for mean
survival timeswere used to estimate a 95% confidence
interval for the difference in life expectancy.
Kaplan-Meier Sample Average (KMSA)
Censor Adjustment for Costs
Following the method described by Etzioni et al.5 to
calculate the KMSA estimator for costs, the trial period
is divided into k timeperiods. Themean costs of all un-
censoredpatients during time intervals t=1 tok ismul-
tiplied by the Kaplan-Meier estimate of the proportion
alive at the beginning of the interval. Summing across
these weighted costs for each interval gives the KMSA
estimator of costs adjusted for censoring. The KMSA is
a consistent estimator ofmean cost when censoring oc-
curs only at the beginning of the interval and is nearly
consistent for small time intervals for any other censor-
ing pattern.6 We use 90-day intervals in the estimation
of the KMSA in our analysis. Lin and colleagues have
provided an estimate of the standard error for these
costs so that a confidence interval for the cost-differ-
ence is straightforward to calculate using standard
methods.6
Censor-Adjusted Bootstrap Interval
The key difference between use of bootstrapping for
uncensoredandcensoredcost-effectivenessdata is that
the latter circumstance requires additional information
on whether the subject is censored at observed follow-
up time t, these data beingpart of the resampling frame.
The procedure also makes greater computational de-
mands, working with censoring adjusted estimators
(e.g., K-M for survival and KMSA for costs) rather than
with simple sample means.
We followed the following procedure:
A sample was drawn (with replacement) of 67 pa-
tients from the control group, with data elements per
patient of survival time, cost and censoring status (yes/
no). This formeda single bootstrap resample of the con-
trol group. A similar sample (n = 81) was drawn from
the treatment group to forma single bootstrap resample
of the treatment group.
1. AKaplan-Meier estimate of censor-adjustedmean sur-
vival (life expectancy) and a KMSA estimate for cen-
sor-adjusted costs was calculated from the bootstrap
resamples of the control and treatment groups.
2. The censor-adjusted cost and effect replicates from
each treatment and control bootstrap resample are
then used to calculate an incremental cost-effective-
ness ratio (ICER)—this beingone replicate of the ICER.
 
Repeating these 2 steps 1000 times generated a vec-
tor of bootstrap replicates of cost-effectiveness results.
The 1000 cost and effect estimates used to calculate the
ICER replicates form the nonparametric estimate of the
joint density of costs and effects.
Censor-Adjusted Fieller’s Interval
The method for estimating a confidence interval for
an ICER using Fieller’s theorem has been presented in
several publications, but always in the context of un-
censored data.1,2,9 Based on the literature reviewed
above, it is clearly possible to derive the relevant cen-
sor-adjusted means and variances for costs and effects
(KMSA and K-M Life Expectancy estimates for treat-
ment and control groups) for input to the Fieller confi-
dence interval formula.
In the absence of an exact solution for the covariance
term with censoring, which is required for the Fieller
method, we present a pragmatic way forward. We use
K-MandKMSAestimators formean survival andcosts,
respectively, for treatment and control groups, and
with relevant variance terms for input into the Fieller
confidence interval formula. Covariance of incremen-
tal costs and effects can be expressed as a function of
variance of incremental costs, variance of incremental
effects, and correlation between incremental costs and
effects: cov( , ) * var( )* var( )∆ ∆ ∆ ∆E C E C= ρ . Because
wehave inputs necessary to estimate the variance of in-
cremental costs and effects, an indirect method of esti-
mating the covariance of incremental costs and effects
is to assumea specific correlation (ρ) betweencosts and
effects.
For the correlation between censored costs and ef-
fects (ρ), we examined 2 options: 1) an assumed effect-
cost correlation ranging from –1 to +1, including 0 for
cost and effect independence; 2) an approximated cor-
relation based on the Pearson correlation between the
cost and effect data without censoring adjustment (i.e.,
time-on-studywithall patients assumed to “respond”).
RESULTS
Using observed time-on-study andassuming all cen-
sored observations are responders (deaths) yields sur-
vival of 1.34 years with control and 1.98 years with
treatment; difference of 0.64 years in favor of treatment
(95%CI 0.30 to 0.98). The K-M estimates (without cen-
sor adjustment) formean survival were 1.53 years with
control and 2.07 years with treatment, a difference in
favor of treatment of 0.54 years (95% CI 0.16 to 0.92).
Mean cost per patient without censoring adjustments
was 363.9with control and 451.8with treatment; a cost
increase with treatment of 87.9 (95% CI –5.0 to 180.8).
Adjusting costs for censoring, the KSMA estimates are
395.8 with control and 467.8 with treatment, a cost in-
crease with treatment of 72 (95% CI –23.4 to 167.4).
Overall, the ICER with no censor adjustments is 139
and with censor adjustment, this falls to 132.
The 1000 bootstrap replicates of censor-adjusted
cost and effect differences are plotted in Figure 1, and
the bootstrap replicates of the associated ICERs are rep-
resented by the slopes of the lines joining these points
to the origin. Confidence intervals for the ICER are esti-
mated from the 2.5th and 97.5th percentiles of a rank
ordering of the ICER replicates, with negative ICERs in
the northwest quadrant of the plane appearing at the
top of the rank order. The estimated percentile confi-
dence interval limits are –52 to 504, the negative lower
limit indicating treatment could dominate control (less
costly and more effective).
The ICER confidence intervals for the bootstrap and
Fieller methods with censoring (and for bootstrap
without censoring) are presented in Table 1. Com-
paring the bootstrap method with and without censor-
ing adjustment indicates little impact on the point esti-
mate of the ICER, but censoring adjustment widens the
confidence interval by 40% (from 398 to 556). The
Fieller confidence interval depends on the assumed
correlation between costs and effects; with perfect neg-
ative correlation, the lengthof the interval is 1017 (from
limits of –25.5 to 991.5), and with perfect positive cor-
relation, the length of the interval is 596 (from limits of
–45.9 to 550.4).
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Figure 1. Cost and effect pairs from 1000 bootstrap samples show-
ingbase case cost-effectivenessand95%confidence intervals (CIs).
 
The relation between alternative assumptions on
cost and effect correlation and the ICER confidence in-
terval is plotted in Figure 2. The size and symmetry of
the confidence interval varies over the range of correla-
tion from –1 (large interval, positive skew) to +1 (small
interval, negative skew). In both Figure 2 and Table 1 is
shown the Fieller interval with approximated
covariance based on uncensored cost-effect correlation
(ρ = 0.05); this is very similar to the bootstrap interval
with censor adjustment, shown by the dashed lines in
Figure2.Thecost-effect correlationcalculated from the
censor adjusted bootstrap replicates is 0.03.
DISCUSSION
This is the first study topresent bootstrap andFieller
methods for cost-effectiveness confidence intervals
with censored cost and effect data. Our data comparing
the uncensored and censored bootstrapdata reveal that
adjustments for censoring have important implications
for both the bias and precision of cost-effectiveness es-
timates. Although the difference in point estimate
(bias) was small, the size of the confidence interval is
substantially increased when necessary adjustments
are made for censoring.
The choice between the censor-adjusted bootstrap
and Fieller method for confidence interval estimation
rests on a number of factors. The computer-intensive
challenge of bootstrapping is no longer a major con-
straint in the era of high-speed computing. The boot-
strapping algorithm involves the re-estimation of mul-
tipleKaplan-Meier curves andKMSAestimators and is
not trivial to set up, but once achieved it offers a robust
method, which preserves the correlation structures
within the data. Although the size and symmetry of the
Fieller’s confidence interval are clearly a function of
the assumed covariance (Figure 2), the similarity be-
tween the Fieller method when employing the unad-
justed correlation and the bootstrap results suggests
thismay be a pragmaticway forward if analystswant to
exploit the relative simplicity of Fieller’s approach.
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